Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Current Deferred Revenue for 8 consecutive years, with $583000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 20.21% year-over-year to $583000.0 in Q2 2026; TTM through Jun 2026 was $583000.0, a 20.21% increase from a year earlier, with the FY2025 full-year figure at $479000.0, down 51.76% from the prior year.
• Current Deferred Revenue was $583000.0 for Q2 2026 at Vivos Therapeutics, up from $495000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $3.0 million in Q4 2022 and troughed at $479000.0 in Q4 2025.
• A 5-year average of $1.7 million and a median of $2.2 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 34.06% in 2023 and plunged 79.73% in 2025, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $3.0 million in 2022, then decreased by 20.11% to $2.4 million in 2023, then tumbled by 59.09% to $993000.0 in 2024, then sank by 51.76% to $479000.0 in 2025, then advanced by 21.71% to $583000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $583000.0 (Q2 2026), $495000.0 (Q1 2026), and $479000.0 (Q4 2025), per Business Quant data.